Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
|Videos|June 13, 2011
Dr. Paz-Ares Discusses Pemetrexed Clinical Trial
Author(s)Luis Paz-Ares, MD, PhD
Dr Paz-Ares from Seville University Hospital Discusses Pemetrexed Clinical Trial
Advertisement
Luis Paz-Ares, MD, PhD, chair of Oncology at Seville University Hospital in Spain, discusses the pemetrexed advanced nonsquamous non—small cell lung cancer clinical trial.
Advertisement
Related to this article
The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.
An OncLive workshop covered practice-changing ROS1- and ALK-directed data in NSCLC shared at ASCO 2026 and beyond.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Lung cancer experts discuss the optimal management of CNS disease in EGFR-mutated non–small cell lung cancer.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.
Risvutatug rezetecan met the primary OS end point of the phase 3 ARTEMIS-008 trial in Chinese patients with relapsed small-cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
Olverembatinib Plus Blinatumomab Yields High Early-Phase CR/CRi Rates in R/R Ph+ CML and B-ALL
4
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
5